Clinical Trials Browser

Phase 2/3 × INDUSTRY × Bevacizumab × Clear all

NCT07221357 2026-03-17

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05945901 2025-11-18

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05141721 2025-05-16

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02414165 2020-02-07

Toca5

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

NCT00384176 2017-04-14

HORIZON III

Phase 2/3 Completed

1,814 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01383148 2017-01-05

TIME

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00735241 2015-05-22

FAST

Phase 2/3 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms